May 20, 2020 / 10:32 PM / 12 days ago

BRIEF-Gilead, Galapagos Announce Topline Results Of Phase 2b/3 Trial In Ulcerative Colitis

May 20 (Reuters) - Galapagos NV:

* GILEAD AND GALAPAGOS ANNOUNCE POSITIVE TOPLINE RESULTS OF PHASE 2B/3 TRIAL OF FILGOTINIB IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

* GALAPAGOS NV - FILGOTINIB 200 MG DEMONSTRATED GREATER EFFICACY COMPARED WITH PLACEBO IN INDUCTION AND MAINTENANCE OF REMISSION IN SELECTION TRIAL

* GALAPAGOS NV - RATES OF ADVERSE EVENTS WERE LOW AND COMPARABLE ACROSS TREATMENT GROUPS

* GALAPAGOS NV - ESTIMATED 40% OF PATIENTS WITH ULCERATIVE COLITIS EXPERIENCE A RELAPSE ANNUALLY AND DO NOT ACHIEVE SUSTAINED REMISSION

* GALAPAGOS NV - FILGOTINIB 100 MG DID NOT ACHIEVE STATISTICALLY SIGNIFICANT CLINICAL REMISSION AT WEEK 10 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below